SEOUL, March 21 (AJP) - Animuscure, a biotech startup founded by Sookmyung Women’s University (SWU) Pharmacy Professor Bae Kyu-un, announced that its drug candidate AMC6156 has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA). The drug is currently being developed to treat Amyotrophic Lateral Sclerosis (ALS).
Commonly known as Lou Gehrig’s disease, ALS is a progressive neurodegenerative disorder characterized by the gradual damage and loss of motor neurons. This leads to muscle weakness, atrophy, and eventually paralysis. The disease typically affects middle-aged and older adults, with a survival period generally estimated between two and five years after the onset of symptoms.
Current medical options to fundamentally stop the progression of ALS remain extremely limited, representing a significant unmet medical need. AniMusCure Inc. (Animuscure) is developing AMC6156 as an oral medication featuring a new mechanism of action aimed at improving muscle function. As an oral formulation, the drug is expected to improve patient convenience, and the company plans to explore combination therapies and commercialization strategies based on future clinical results.
The FDA grants ODD to drugs intended for the treatment of rare diseases affecting fewer than 200,000 people in the United States. This designation provides several incentives for developers, including tax credits for clinical trials, eligibility for federal grants, a waiver of prescription drug user fees, and seven years of market exclusivity upon regulatory approval.
This marks the second FDA ODD for the company. In September 2025, Animuscure received the same designation for AMC8012, a treatment candidate for Duchenne Muscular Dystrophy (DMD), a rare congenital muscle disorder. By securing consecutive designations for muscle and neurological conditions, the company is strengthening its position in the global drug development market.
"With this orphan drug designation as a stepping stone, we will accelerate global clinical development," said CEO Bae Kyu-un. "Our goal is to provide new options for ALS patients who currently have very limited treatment choices."
Copyright ⓒ Aju Press All rights reserved.